title: Current treatment strategy of diffuse large B-cell lymphomas.
abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for approximately 25-30% of all new patients. Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. Rituximab significantly improves treatment outcome in DLBCL. A large-phase III study demonstrated improved overall survival (OS) in patients with DLBCL treated with R-CHOP therapy. The Groupe d'Etude des Lymphomes de l'Adulte (GELA), Eastern Cooperative Oncology Group (ECOG) and German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) studies designed for patients older than 60 years have clearly shown prolonged event-free survival (EFS) and OS among patients who received rituximab and chemotherapy. For patients under 60 years, the MabThera International Trial Group (MInT) study demonstrated improved EFS and OS after the addition of rituximab to CHOP therapy. However, the R-CHOP therapy does not provide a satisfactory treatment outcome in the high-risk group according to the international prognostic index. Therefore, R-CHOP therapy is the new standard therapy in elderly and young, low-risk DLBCL patients. For young, high-risk DLBCL patients, treatment that incorporates rituximab and hematopoietic stem cell transplantation has been administered in clinical studies.
authors.affiliation: Department of Hematology, Saitama Medical University, Hidaka, Saitama, Japan. nniitsu@saitama-med.ac.jp
authors.forename: Nozomi
authors.initials: N
authors.lastname: Niitsu
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000628:therapy*
references.citation: Cancer Treat Rev. 2007 Jun;33(4):338-46
references.pmid: 17400393
references.citation: Blood. 2004 Aug 1;104(3):626-33
references.pmid: 14982884
references.citation: Ann Intern Med. 1985 May;102(5):596-602
references.pmid: 2580468
references.citation: J Clin Oncol. 2007 Mar 1;25(7):787-92
references.pmid: 17228021
references.citation: Blood. 2002 Feb 1;99(3):754-8
references.pmid: 11806974
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4117-26
references.pmid: 15867204
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Lancet Oncol. 2006 May;7(5):379-91
references.pmid: 16648042
references.citation: N Engl J Med. 1993 Apr 8;328(14):1002-6
references.pmid: 7680764
references.citation: Lancet Oncol. 2008 Feb;9(2):105-16
references.pmid: 18226581
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3032-8
references.pmid: 15210738
references.citation: N Engl J Med. 1993 Sep 30;329(14):987-94
references.pmid: 8141877
references.citation: Blood. 2003 Dec 15;102(13):4284-9
references.pmid: 12920037
references.citation: N Engl J Med. 1998 Jul 2;339(1):21-6
references.pmid: 9647875
references.citation: Cancer. 1978 Oct;42(4):1705-10
references.pmid: 361209
references.citation: Haematologica. 2006 Jan;91(1):96-103
references.pmid: 16434377
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3121-7
references.pmid: 16754935
references.citation: Blood. 1994 Jan 15;83(2):435-45
references.pmid: 7506951
references.citation: J Clin Oncol. 2008 May 10;26(14):2258-63
references.pmid: 18413640
references.citation: Hematol Oncol. 2010 Jun;28(2):68-74
references.pmid: 20235332
references.citation: Leukemia. 2009 Apr;23(4):777-83
references.pmid: 19151788
references.citation: N Engl J Med. 2005 Mar 24;352(12):1197-205
references.pmid: 15788496
references.citation: J Clin Oncol. 1991 Jan;9(1):25-38
references.pmid: 1702144